Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-05-22 |
AC Immune (Switzerland) Essex Bio-Technology (China) |
undisclosed novel protein therapeutic for the treatment of neurodegenerative diseases and neuroinflammation. |
Neurodegenerative diseases, neuroinflammation. |
research - R&D |
Neurodegenerative diseases |
Research agreement |
2017-05-18 |
Teva Pharmaceutical Industries (Israel) Heptares Therapeutics (UK) |
small-molecule calcitonin gene-related peptide (CGRP) antagonists |
migraine |
licensing - development - commercialisation |
CNS diseases - Neurological diseases |
Milestone |
2017-05-18 |
Anagenesis Biotechnologies (France) Boehringer Ingelheim (Germany) |
Paraxial Mesoderm Multipotent Cells (P2MCs) technology |
chronic muscle diseases |
R&D -research |
Muscle disorders |
Research agreement |
2017-05-16 |
Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany) |
NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab) |
metastatic pancreatic cancer, metastatic colorectal cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-05-16 |
Oryzon Genomics (Spain) |
|
|
nomination |
|
Nomination |
2017-05-16 |
Cambrex (USA - NJ) |
|
|
construction of new premises |
Technology - Services |
Construction of new premises |
2017-05-16 |
Boehringer Ingelheim (Germany) |
commercial production site for biopharmaceuticals in China |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-05-16 |
Boehringer Ingelheim (Germany) Peking University (China) |
|
|
collaboration |
Cancer - Oncology - Cardiovascular diseases - CNS diseases - Immunological diseases - Metabolic diseases - Respiratory diseases |
Collaboration agreement |
2017-05-16 |
Lysogene (France) |
chief operating officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-05-15 |
Akebia Therapeutics (USA - MA) Vifor Pharma (Switzerland) Fresenius Medical Care (Germany) |
vadadustat |
anemia associated with chronic kidney disease |
licensing |
Kidney diseases - Renal diseases |
Licensing agreement |
2017-05-15 |
CytomX Therapeutics (USA - CA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-05-15 |
Takeda Pharmaceutical (Japan) Bushu Pharmaceuticals (Japan) Spera Pharma (Japan) |
|
|
restructuring |
|
Restructuring |
2017-05-15 |
Bioverativ (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Hematological diseases |
Nomination |
2017-05-12 |
Newron (Italy) Zambon (Italy) |
safinamide |
Parkinson's disease |
collaboration - licensing |
Neurodegenerative diseases - CNS diseases |
Milestone |
2017-05-12 |
Emergent BioSolutions (USA - MD) |
newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) |
|
opening of new premises |
Infectious diseases |
Opening of new premises |
2017-05-12 |
Molecular Partners (Switzerland) |
chief executive officer |
|
nomination |
|
Nomination |
2017-05-10 |
Chugai Pharmaceutical (Japan) JW Pharmaceutical (Republic of Korea) |
emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) |
hemophilia A |
licensing |
Rare diseases - Genetic diseases - Hematological diseases |
Licensing agreement |
2017-05-10 |
Selvita (Poland) |
research site in Poznan |
|
opening of new premises |
|
Opening of new premises |
2017-05-09 |
Vaximm (Germany) Merck KGaA (Germany) Pfizer (USA - NY) |
VXM01 and avelumab (MSB0010718C) |
colorectal cancer, glioblastoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-05-09 |
Kymab (UK) |
|
|
nomination |
|
Nomination |